Spago Nanomedical held its 2026 Annual General Meeting
The AGM approved financial statements, re-elected board members, and authorized share issuance for up to 20% of outstanding shares.
See the latest news and media coverage for Spago Nanomedical. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage nanomedicines company
spagonanomedical.seLast updated
In short: Spago Nanomedical advanced its Tumorad-01 clinical trial, reached key research milestones, and initiated a SEK 16 million rights issue to fund development.
The AGM approved financial statements, re-elected board members, and authorized share issuance for up to 20% of outstanding shares.
The rights issue of approximately SEK 16 million is for existing shareholders and the document is registered with the Swedish Financial Supervisory Authority.
Proceeds will fund phase I completion and phase IIa preparation of Tumorad-01 study; major shareholders committed to about 64 percent of the issue.
The presentation showed visible tumor uptake in two head and neck cancer patients from the Tumorad-01 study.
Spago Nanomedical has released the information document for its rights issue of SEK 16.2 million. The Emissions Guide raises one positive and two negative flags.
Spago Nanomedical has decided on a rights issue of approximately 16 million kronor, according to a press release.
LUND, SE / ACCESS Newswire / May 19, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical's annual report for 2025 is from today available at the...
This English version of the notice to the Annual General Meeting is for convenience only. The shareholders of Spago Nanomedical AB (publ), corporate registration number...
Track Spago Nanomedical and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.